Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms.
about
Actin cytoskeletal control during epithelial to mesenchymal transition: focus on the pancreas and intestinal tractTranscriptomic Profiling of Posterior Polymorphous Corneal Dystrophy.CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis.Global profiling of alternative RNA splicing events provides insights into molecular differences between various types of hepatocellular carcinomaIdentification of a Novel Human E-Cadherin Splice Variant and Assessment of Its Effects Upon EMT-Related Events.Connecting the dots: chromatin and alternative splicing in EMT.RNA-binding protein CELF1 promotes tumor growth and alters gene expression in oral squamous cell carcinoma.Epigenetic regulation of ZEB1-RAB25/ESRP1 axis plays a critical role in phenylbutyrate treatment-resistant breast cancer.Expression of SRSF3 is Correlated with Carcinogenesis and Progression of Oral Squamous Cell Carcinoma.CD82 suppresses CD44 alternative splicing-dependent melanoma metastasis by mediating U2AF2 ubiquitination and degradationEpithelial splicing regulatory protein 1 and 2 paralogues correlate with splice signatures and favorable outcome in human colorectal cancer.Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer.Epithelial-mesenchymal transition is regulated at post-transcriptional levels by transforming growth factor-β signaling during tumor progression.Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer.The role of small GTPases of the Rho/Rac family in TGF-β-induced EMT and cell motility in cancer.Connecting myelin-related and synaptic dysfunction in schizophrenia with SNP-rich gene expression hubs.Maid is a negative regulator of transforming growth factor-β-induced cell migration.Splicing-factor alterations in cancers.Aberrant Splicing in Cancer: Mediators of Malignant Progression through an Imperfect Splice Program Shift.EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression.The Arkadia-ESRP2 axis suppresses tumor progression: analyses in clear-cell renal cell carcinomaIDH1 mutation-associated long non-coding RNA expression profile changes in glioma.The RNA-binding protein ESRP1 promotes human colorectal cancer progression.The ESRP1-GPR137 axis contributes to intestinal pathogenesis.Snail suppresses cellular senescence and promotes fibroblast-led cancer cell invasion.Regulation of epithelial-mesenchymal transition in breast cancer cells by cell contact and adhesion.Dual Roles for Epithelial Splicing Regulatory Proteins 1 (ESRP1) and 2 (ESRP2) in Cancer Progression.Establishment of Synergistic Chemoimmunotherapy for Head and Neck Cancer Using Peritumoral Immature Dendritic Cell Injections and Low-Dose Chemotherapies.Genome-wide screen for differentially methylated long noncoding RNAs identifies Esrp2 and lncRNA Esrp2-as regulated by enhancer DNA methylation with prognostic relevance for human breast cancer.ESRP1 is overexpressed in ovarian cancer and promotes switching from mesenchymal to epithelial phenotype in ovarian cancer cells.Signaling Pathways Driving Aberrant Splicing in Cancer Cells.Mesenchymal splice isoform of CD44 (CD44s) promotes EMT/invasion and imparts stem-like properties to ovarian cancer cells.Silencing the Snail-dependent RNA splice regulator ESRP1 drives malignant transformation of human pulmonary epithelial cells.Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment.Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.
P2860
Q28082719-5F1398AE-03E8-438F-88F3-41CA46B960E0Q33847709-6D34DEED-37F2-4EEF-B5FA-ACF1ADAFD84BQ36037993-5B7BFB5B-41E3-4ADC-A1C2-56066E5D9FD5Q36114523-8A563A84-8AA7-4D90-A44B-65AD074CF179Q36147466-E76417CC-3C5D-48A4-8B79-F8AB63F13947Q36441240-545B8EB5-7CC5-42DA-B097-5BCC35DCF667Q36685461-ECEC4E73-F4CF-49AD-8F34-8FF0BCD64C14Q36738957-439FE5F3-9B3B-4FA5-B87D-E7E4A72125A8Q37096920-B1418F44-D5A4-4599-B06D-CC0B8DC34362Q37276868-FF1347CA-9F2F-4CB2-8754-3A087641D3C1Q37687476-7C6D2AA1-8501-411F-A952-01980DA27357Q37709301-C70B8D5D-9653-425D-A6EC-4C201775B4B7Q38349021-BE063E2C-C003-4F17-B9D0-F81652A75CD4Q38698070-D31D1EC9-DB45-4947-9A2A-639FCD4EBA13Q38846822-4C831190-6C8E-4BF6-91FB-AE466A3994E4Q38850829-A362B420-F1D9-45A9-9102-8E109C1E14DBQ38871732-58C7D3EA-62FE-45AE-A5C0-B2D70E7F682AQ38929098-C1576E9A-09FE-4734-B46B-C66FC93CE033Q38994370-D3A0D34E-9E22-4182-A1B2-2EE4511A019EQ39109931-BB6AA16F-D414-4F86-90F8-36498CD7D17EQ40368929-4739D751-9E5E-49F6-81FC-8B2EF36C3F13Q40576605-EB54FB7A-F653-424B-ADF4-A72A2DED902BQ41835902-1D7536EC-2B9C-4B9E-BF18-D853E4DEA1D4Q41991370-390105F0-63C4-4342-BC54-6A4F781B0CA5Q42288796-4405F18C-9919-4D88-AE39-2DD5E84FCF7DQ43144068-B874EFBF-2753-49FA-A4FE-1679EA3C923FQ46518039-18301DDA-3EA9-4E76-9F08-68F19DFCC0B6Q47096374-5C97822D-38B4-4004-97CA-F33B0B41668DQ47111892-CED7202C-CDC9-431D-B1E2-E22F29427909Q47138140-CF75170F-238B-4D50-ABD7-0D8ACA217DCEQ47246029-11751650-8AAF-4F80-8812-2CAB4C991F87Q48318565-64E9104F-9FA7-4DB3-B71F-A098E82E9033Q50066565-DC2DDCD9-92E0-4C5F-9AAB-726A391987B8Q50133361-EDFE1378-E809-4AE0-9D51-530357DADCA1Q52564290-A7F31A45-4A96-49E8-8253-0C4A018ED0C4
P2860
Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Epithelial splicing regulatory ...... lity via different mechanisms.
@en
type
label
Epithelial splicing regulatory ...... lity via different mechanisms.
@en
prefLabel
Epithelial splicing regulatory ...... lity via different mechanisms.
@en
P2093
P2860
P356
P1476
Epithelial splicing regulatory ...... ility via different mechanisms
@en
P2093
Hiroki Ishii
Kei Sakamoto
Keisuke Masuyama
Masao Saitoh
Mitsuyoshi Motizuki
Ryohei Katoh
Shota Tanaka
Tetsuo Kondo
P2860
P304
27386-27399
P356
10.1074/JBC.M114.589432
P407
P50
P577
2014-08-20T00:00:00Z